Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "739-Cr"

3 News Found

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr
News | April 30, 2026

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth
News | February 12, 2026

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr
News | August 10, 2025

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a

Latest Stories

BD, Suttons Creek partner to streamline combination product development

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India
Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India
Kavinder Beniwal Chief Operational Officer, Motorica India
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.

Packaging